Neuroprotective effects of ellagic acid on cuprizone-induced acute demyelination through limitation of microgliosis, adjustment of CXCL12/IL-17/IL-11 axis and restriction of mature oligodendrocytes apoptosis

Pharm Biol. 2017 Dec;55(1):1679-1687. doi: 10.1080/13880209.2017.1319867.

Abstract

Context: Ellagic acid (EA) is a natural phenol antioxidant with various therapeutic activities. However, the efficacy of EA has not been examined in neuropathologic conditions.

Objective: In vivo neuroprotective effects of EA on cuprizone (cup)-induced demyelination were evaluated.

Material and methods: C57BL/6 J mice were fed with chow containing 0.2% cup for 4 weeks to induce oligodendrocytes (OLGs) depletion predominantly in the corpus callosum (CC). EA was administered at different doses (40 or 80 mg/kg body weight/day/i.p.) from the first day of cup diet. Oligodendrocytes apoptosis [TUNEL assay and myelin oligodendrocyte glycoprotein (MOG+)/caspase-3+ cells), gliosis (H&E staining, glial fibrillary acidic protein (GFAP+) and macrophage-3 (Mac-3+) cells) and inflammatory markers (interleukin 17 (IL-17), interleukin 11 (IL-11) and stromal cell-derived factor 1 α (SDF-1α) or CXCL12] during cup intoxication were examined.

Results: High dose of EA (EA-80) increased mature oligodendrocytes population (MOG+ cells, p < 0.001), and decreased apoptosis (p < 0.05) compared with the cup mice. Treatment with both EA doses did not show any considerable effects on the expression of CXCL12, but significantly down-regulated the expression of IL-17 and up-regulated the expression of IL-11 in mRNA levels compared with the cup mice. Only treatment with EA-80 significantly decreased the population of active macrophage (MAC-3+ cells, p < 0.001) but not reactive astrocytes (GFAP+ cells) compared with the cup mice.

Discussion and conclusion: In this model, EA-80 effectively reduces lesions via reduction of neuroinflammation and toxic effects of cup on mature OLGs. EA is a suitable therapeutic agent for moderate brain damage in neurodegenerative diseases such as multiple sclerosis.

Keywords: Antioxidant; multiple sclerosis; neurodegeneration; neuroinflammation; toxic demyelination.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Chemokine CXCL12 / metabolism
  • Corpus Callosum / drug effects
  • Corpus Callosum / metabolism
  • Cuprizone / toxicity*
  • Demyelinating Diseases / prevention & control*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects
  • Ellagic Acid / administration & dosage
  • Ellagic Acid / pharmacology*
  • In Situ Nick-End Labeling
  • Interleukin-11 / metabolism
  • Interleukin-17 / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology*
  • Oligodendroglia / drug effects
  • Oligodendroglia / metabolism
  • RNA, Messenger / metabolism
  • Up-Regulation / drug effects

Substances

  • Chemokine CXCL12
  • Interleukin-11
  • Interleukin-17
  • Neuroprotective Agents
  • RNA, Messenger
  • Ellagic Acid
  • Cuprizone

Grants and funding

The authors thank the Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences (PSRC) for supporting the doctoral program (PhD) of the first author. This work was supported by funds from Tehran University of Medical Sciences and Health Services, Tehran, Iran.